About Keratin, type II cuticular Hb5
Keratin, type II cuticular Hb5 (KRT85) is a protein
from Homo sapiens identified by UniProt accession
P78386, 507 residues long.
MolForge cross-references it against 0 known binders and
22 disease associations.
Target properties
| Protein name | Keratin, type II cuticular Hb5 |
| UniProt accession | P78386 |
| Gene | KRT85 |
| Organism | Homo sapiens |
| Length | 507 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (22)
Diseases linked to this target (Open Targets).
- pure hair and nail ectodermal dysplasia · score 0.59
- ovarian cancer · score 0.18
- head and neck squamous cell carcinoma · score 0.18
- prostate adenocarcinoma · score 0.18
- clear cell renal carcinoma · score 0.18
- breast adenocarcinoma · score 0.18
- thyroid gland adenocarcinoma · score 0.16
- actinic keratosis · score 0.03
- psoriasis · score 0.01
- cancer · score 0.01
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P78386-F1 | alphafold | PREDICTED | 72.12 | — |
Amino-acid sequence (507 residues)
MSCRSYRISS GCGVTRNFSS CSAVAPKTGN RCCISAAPYR GVSCYRGLTG FGSRSLCNLG SCGPRIAVGG FRAGSCGRSF GYRSGGVCGP SPPCITTVSV NESLLTPLNL EIDPNAQCVK QEEKEQIKSL NSRFAAFIDK VRFLEQQNKL LETKWQFYQN QRCCESNLEP LFSGYIETLR REAECVEADS GRLASELNHV QEVLEGYKKK YEEEVALRAT AENEFVVLKK DVDCAYLRKS DLEANVEALV EESSFLRRLY EEEIRVLQAH ISDTSVIVKM DNSRDLNMDC IIAEIKAQYD DVASRSRAEA ESWYRSKCEE MKATVIRHGE TLRRTKEEIN ELNRMIQRLT AEIENAKCQR AKLEAAVAEA EQQGEAALSD ARCKLAELEG ALQKAKQDMA CLLKEYQEVM NSKLGLDIEI ATYRRLLEGE EHRLCEGVGS VNVCVSSSRG GVSCGGLSYS TTPGRQITSG PSAIGGSITV VAPDSCAPCQ PRSSSFSCGS SRSVRFA
Explore Keratin, type II cuticular Hb5 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets